Mina Ryten
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (22)
Background Prognosis and therapeutic management in Parkinson's disease is a challenging task by its highly heterogeneous disease progression and symptoms presentation, lacking biomarkers to predict individual disease trajectories. Objective To determine whether baseline blood transcriptomes, analyzed through biologically defined pathway gene sets, contain signatures that distinguish distinct motor and non-motor progression trajectories in Parkinson's disease. Methods We developed a pathway-based computational framework to derive individualized molecular severity scores from baseline blood transcriptomic profiles, integrating pathway-level gene expression with longitudinal clinical data. Domain-specific severity indices were generated for motor and non-motor features and used to model progression trajectories in sporadic Parkinson's disease within the Parkinson's Progression Markers Initiative cohort. Machine learning models assessed baseline predictability of trajectory membership. Findings were independently validated in genetic cohorts and externally in the Parkinson's Disease Biomarkers Program cohort. Results Baseline molecular severity scores were associated with key clinical features. Analysis of score changes revealed two distinct non-motor and two distinct motor progression groups, each underpinned by specific gene signatures (20 genes for non-motor; 121 for motor). Machine learning models predicted an individual's trajectory group from baseline transcriptomic data with high accuracy (0.87 for motor progression). The framework demonstrated robust generalizability across independent and genetic cohorts, producing clinically coherent profiles. Conclusions Blood transcriptomes define clinically distinct PD progression subtypes via pathway-level signatures, with motor and non-motor trajectories driven by largely independent molecular programs from baseline. This biologically informed stratification is generalizable across cohorts and provides a novel framework for estimating patient prognosis and moving toward precision medicine in Parkinson's disease.
Year:
2026
Profiling dynamic molecular processes in neurodegeneration in vivo remains a major clinical challenge. Limited brain tissue accessibility especially limits the development and effective deployment of emerging disease modifying therapies, highlighting the need for non-invasive methods for profiling molecular disease processes. We introduce a non-invasive imaging framework that integrates ultra-high-resolution 7T quantitative MRI (qMRI) with spatially-resolved transcriptomics (SRT) to infer cell-type and pathway-specific molecular features within the cortical grey matter. We demonstrate that our method predicts from qMRI data disease-associated changes to cell type proportions and molecular pathways within the grey matter cortex which are corroborated by orthogonal datasets, including bulk RNA sequencing, single nucleus RNA sequencing and high-performance liquid chromatography. This proof-of-concept establishes the integration of qMRI and SRT as a scalable, non-invasive platform for molecular profiling in neurodegeneration, with significant potential for precision therapeutic monitoring, drug development and clinical trials.
Year:
2026
Evidence links air pollution to dementia, yet its role in Lewy body dementia (LBD) remains unclear. In this work, we showed in a cohort of 56.5 million individuals across the United States that fine particulate matter (PM 2.5 ) exposure raises LBD risk. Mechanistically, we found that PM 2.5 exposure led to brain atrophy in wild-type mice, an effect not seen in α-synuclein (αSyn)–deficient mice. PM 2.5 exposure generated a highly pathogenic αSyn strain, PM 2.5 –induced preformed fibril (PM-PFF), with enhanced proteinase K resistance and neurotoxicity, resembling αSyn LBD strains. PM 2.5 samples from China, the United States, and Europe consistently induced proteinase-resistant αSyn strains and in vivo pathology. Transcriptomic analyses revealed shared responses between PM 2.5 -exposed mice and LBD patients, underscoring PM 2.5 ’s role in LBD and stressing the need for interventions to reduce air pollution and its associated neurological disease burden.
Year:
2025
Parkinson’s disease (PD) exhibits substantial clinical and molecular heterogeneity, driven in part by mutations in SNCA , GBA1 and LRRK2 genes. Understanding how these genetic subtypes differ in progression and peripheral transcriptomic profiles may inform personalized prognostic and therapeutic strategies. In this study, we aim to compare disease progression trajectories and blood-based gene expression patterns among SNCA -positive ( SNCA+ ), GBA -positive ( GBA+ ) and LRRK2 -positive ( LRRK2+ ), and sporadic PD patients, and to identify shared and subtype-specific transcriptional signatures. We used well-characterized cohorts of SNCA + (n=26), GBA + (n=70), LRRK2 + (n=147), and sporadic (n=387) PD patient from the Parkinson’s Progression Markers Initiative (PPMI) cohort. We used data from samples collected 6 months after baseline visit for differentially expressed gene (DEGs) analysis, controlling for cell type proportions. Our results show that SNCA + patients had the earliest onset and poorest survival, whereas LRRK2 + and sporadic PD progressed more slowly. GBA + and LRRK2 + patient groups exhibited prominent immune-related activation, with overlapping upregulated DEGs between LRRK2 + and GBA + and shared downregulation between LRRK2 + and SNCA +. No significant blood DEGs distinguished favourable and unfavourable outcomes in sporadic PD cases. In conclusion, mutation-specific clinical trajectories and systemic inflammatory signatures in GBA + and LRRK2 + PD underscore the promise of blood-based biomarkers, warranting validation in larger and tissue-targeted studies.
Year:
2025
The entorhinal cortex (ERC) is implicated in early progression of Alzheimer’s disease (AD). Here we investigated the impact of established biological risk factors for AD, including APOE genotype (E2 versus E4 alleles), sex, and ancestry, on gene expression in the human ERC. We generated paired spatially-resolved transcriptomics (SRT) and single-nucleus RNA sequencing data (snRNA-seq) in postmortem human ERC tissue from middle aged brain donors with no history of AD. APOE -dependent changes in gene expression predominantly mapped to a transcriptionally-defined oligodendrocyte subtype, which varied substantially with ancestry, and suggested differences in oligodendrocyte differentiation and myelination. Integration of SRT and snRNA-seq data identified a common gene expression signature associated with APOE genotype, which we localized to the same oligodendrocyte subtype and a white matter spatial domain. This suggests that AD risk in ERC may be associated with disrupted oligodendrocyte function, potentially contributing to future neurodegeneration. Lay Summary Alzheimer’s disease (AD) is a neurodegenerative disorder that accounts for 60-80% dementia cases. Apolipoprotein E ( APOE) genotype is the strongest genetic risk factor for AD, and the entorhinal cortex (ERC) is a brain region implicated in its earliest progression. Our study investigated how APOE genotype impacts gene expression in the ERC. We identified genotype-dependent effects on oligodendrocytes with different transcriptional profiles related to maturation that may help explain how APOE genotype mediates its effects on AD risk.
Year:
2025
Dementia in Lewy body diseases (LBD) is common and arises through heterogeneous and incompletely understood pathways. Evidence suggests contributions from genetic factors, including APOE ε4 genotype, co-pathology including concomitant Alzheimer’s disease pathology and hypoperfusion related to orthostatic hypotension. However, the relative impact of these factors remains unclear. To address this, we analysed 399 post-mortem brains from LBD cases comprising Parkinson’s disease, Parkinson’s disease dementia and dementia with Lewy bodies, and controls, integrating APOE genotype, clinical data and assessment of ischaemic pathology alongside large-scale digital pathology quantification. We established an image analysis pipeline utilising machine learning to enable automated, standardised measurement of α-synuclein, amyloid-β, and phosphorylated tau burden across multiple brain regions. Quantitative pathology strongly correlated with semi-quantitative ratings and outperformed conventional staging in predicting dementia. Across multiple analytical approaches, APOE ε3 and ε4 carriers showed distinct dementia risk profiles. APOE ε3 carriers developed dementia at lower quantitative α-synuclein and amyloid-β thresholds than ε4 carriers, although overall dementia risk was dominated by ε4 genotype, consistent with ε4 both promoting greater pathology accumulation and modifying the threshold for dementia onset. Orthostatic hypotension and ischaemic pathology increased dementia risk only in ε3 carriers with low Lewy and Alzheimer’s proteinopathy burden, while male sex further modulated dementia risk for this subgroup. A data-driven progression model (SuStaIn) identified four trajectories of Lewy pathology: two corresponding to recognised patterns, one brainstem-first and the other with early amygdala involvement, and two representing novel cortical-onset patterns, one with early cingulate cortex involvement and the other starting in neocortex before limbic and brainstem involvement. Co-pathology progression modelling identified subtypes with early predominance of amyloid-β, phosphorylated tau, or α-synuclein, and showed that Lewy subtypes follow two propagation trajectories in opposite directions. Together, these findings demonstrate that integrating quantitative pathology with genotype and clinical data uncovers distinct yet overlapping pathways to dementia in LBD, refining disease progression models and providing a basis for genotype- and pathology-informed patient stratification in therapeutic trials.
Year:
2025
Introductory paragraph While mRNA splicing dysregulation is a well-established contributor to neurodegeneration in disorders such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), its role in Parkinson’s disease (PD) remains underexplored. Here, we analyse transcriptomic data from >500 post-mortem human brain samples from individuals with and without PD to show that splicing alterations are frequently detected. Differentially spliced genes were significantly more enriched for those causally-implicated in both PD and ALS than genes that were differentially expressed. Furthermore, we observed a strong association between these splicing alterations and dysfunction of the RNA-binding protein (RBP), TAR DNA-binding protein 43 (TDP-43). Strikingly, genes and exon junctions affected by TDP-43 knockdown overlapped significantly with those dysregulated across brain regions in PD. In brains from individuals with the LRRK2 c.6055G>A (p.G2019S) mutation, the most common genetic cause of PD, we also observed significant enrichment of TDP-43-dependent splicing changes. This finding was corroborated in human pluripotent stem cell-derived midbrain dopaminergic neurons and a LRRK2 p.G2019S knock-in mouse model, where reduced nuclear TDP-43 levels evidenced the well-recognised loss-of-function mechanism contributing to splicing dysregulation. By leveraging our RNA-based analyses we predicted TDP-43-dependent novel peptide sequences and validated their existence within human LRRK2 mutation mDNs, while also demonstrating an overall loss of protein and mRNA expression in mis-spliced genes. Collectively, our findings reveal that PD is marked by extensive splicing dysregulation dependent on TDP-43, making TDP-43 a promising new therapeutic target in PD.
Year:
2025
Parkinson’s disease (PD) is characterised by insoluble α-synuclein (αSyn) aggregates in Lewy bodies (LBs) within the substantia nigra, with cortical pathology appearing as the disease progresses. Late-stage LB deposition, cellular stress, and neuronal loss obscure disease-driving events, we therefore performed multi-regional transcriptomic and aggregate profiling in early-midstage PD brains (Braak 3–4), where cortical regions are pathologically unaffected. We report neuroimmune activation as an early PD feature, characterised by the expansion of a high- SNCA -expressing microglial state. This robust immune signature occurs prior to LB formation, but is associated with oligomeric αSyn within cortical microglia. In hiPSC-derived microglia, both endogenous αSyn oligomerisation, and exogenous oligomer uptake, trigger transcriptional reprogramming, characterised by interferon-driven inflammation, antigen presentation, and mitochondrial suppression, closely mirroring the early PD brain. These findings describe mechanisms by which αSyn oligomerisation potently initiates early neuroinflammation, highlighting a critical interplay between proteinopathy and immune activation at the earliest stages of disease.
Year:
2025
Early cellular events in Parkinson’s disease (PD) remain elusive. While aggregation of α-synuclein (αSyn) into Lewy bodies marks advanced pathology, smaller αSyn oligomers have been implicated in prodromal stages. Here we map αSyn oligomers at single-particle resolution in post-mortem brain tissue from Braak stage 3/4 PD cases and matched controls. Quantitative imaging of 9,882 neurons across four regions captured over 112 million αSyn oligomers. Mean intracellular α-Syn burden was unchanged between groups, but PD samples contained a higher fraction of neurons whose oligomer load exceeded a specific aggregation threshold. We term these aggregation-susceptible cells (ASCs). ASC enrichment in vulnerable regions supports a population-level model in which early pathology arises from a stochastic shift in cellular composition rather than altered αSyn aggregation kinetics. This human-tissue, large-scale dataset provides a quantitative framework for detecting ASCs and for testing population-level interventions in PD and related proteinopathies.
Year:
2025
Long-read RNA sequencing has expanded our understanding of the transcriptome, revealing unannotated transcripts. However, interpreting their functional relevance remains challenging. To address this, we developed TX2P, a user-friendly tool that integrates transcriptomic and proteomic data to link RNA discoveries with protein function. Applied to epilepsy-associated genes, TX2P identified novel protein-coding transcripts, with peptide evidence supporting 17.2% transcripts and 18.0% of unique open reading frames. By seamlessly integrating transcriptomic and proteomic insights, TX2P facilitates transcriptome interpretation.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2022
Collaborators (69)
Minee-Liane Choi
Assistant Professor
Korea Advanced Institute of Science and Technology
Tammaryn Lashley
University College London
Dirk Hockemeyer
Associate Professor
University of California, Berkeley
Helene Plun-Favreau
Professor
UCL Institute of Neurology, University College London
Gabriele Siegel
University of Zurich
Frank Soldner
Assistant Professor
Albert Einstein College of Medicine
Henrik Zetterberg
Professor
University of Gothenburg
Zhongbo Chen
The Francis Crick Institute
Annemieke Aartsma-Rus
Professor of Translational Genetics
Leiden University Medical Center
Yau Mun Lim
University College London
Mark Chaisson
Associate Professor
University of Southern California
Ramin Nilforooshan
Professor in Psychiatry
University of Surrey
Minhan Park
Georgia Institute of Technology
Regina Reynolds
University College London
Frances Platt
Head of Department
University of Oxford
Juan A. Botía
University College London
Xuan Zhang
Assistant Professor
University of California Merced
Michele Vendruscolo
Professor
University of Cambridge
Selina Wray
Professor of Molecular Neuroscience
UCL Institute of Neurology, University College London
Cynthia Sandor
-
Alexander Pantelyat
Associate Professor
Johns Hopkins University
Ramhari Kumbhar
Research associate
Johns Hopkins University School of Medicine
Keri Martinowich
-
Timothy Yu
Associate Member
Broad Institute
Henry Houlden
Professor of Neurogenetics
-
Raquel Real
University College London
Nick Fox
Professor and Head of Department
UCL Institute of Neurology, University College London
Philip Wong
Professor
Johns Hopkins University
Steven F. Lee
Professor of Biophysical Chemistry
University of Cambridge
Sebastian Brandner
University College London
Payam Barnaghi
Professor of Machine Intelligence Applied to Medicine
Imperial College London
Alice Davidson
Professor of Molecular Genetics
University College London
Rodney Weber
Georgia Institute of Technology
Maya Chopra
Director of Translational Genomic Medicine
Boston Children's Hospital
Danny Miller
Assistant Professor
University of Washington
Sarah Marzi
Senior Lecturer
King’s College London
Xiao Wu
Assistant Professor
Columbia University Mailman School of Public Health
Anne Gregor
Senior Researcher
University Hospital of Bern
Matthis Synofzik
Professor
Hertie Institute for clinical brain research
Dario R. Alessi
University of Dundee
Paul Gissen
University College London
Matthew J. Farrer
Director of Clinical Genomics
University of Florida
Thomas Warner
University College London
Sara Mole
University College London
Xiaobo Mao
Associate Professor
Johns Hopkins University School of Medicine
Nicholas Wood
University College London
Amanda Heslegrave
Principal Research Fellow
University College London
Emil Gustavsson
Assistant Research Professor
University of Cambridge
Kevin Mills
University College London
Mathew Horrocks
Full Professor of Biophysics
University of Edinburgh
Shizhong Han
Lead Investigator
Johns Hopkins University School of Medicine
Huw Morris
University College London
david nauen
Johns Hopkins University School of Medicine
Joseph Beckwith
Assistant Professor
University of Warwick
Maria Rodriguez-Lopez
Head of Genomics Facility
Babraham Institute
Leonardo Collado-Torres
Assistant Professor
Johns Hopkins University
Lucien Weiss
Associate Professor
Polytechnique Montréal
Tatiana Alvarez Giovannucci
Karolinska Institutet
Katie Lunnon
Associate Professor
University of Exeter
Philippa Mills
Professor of Inherited Metabolic Diseases
University College London
Gregory Costain
Hospital for Sick Children
Boyi Guo
Assistant Professor
University of Utah Health
Pengfei Liu
Georgia Institute of Technology
Stephan Sanders
Professor of Paediatric Neurogenetics
University of Oxford
Martina F Callaghan
University College London
Hormos Salimi Dafsari
Max Planck Institute for Biology of Ageing
Jose Palma
Associate Professor in Computer Science and Artificial Intelligence
Universidad de Murcia
Zane Jaunmuktane
Clinical Lecturer and Honorary Consultant Neuropathologist
UCL Institute of Neurology, University College London
Weiyi Peng
Director
University of Houston
Make your next move.
Prepare your application
Review drafts before you send them.